In an early-phase study, PCI-32765, a BTK inhibitor, was shown to work against CLL, a type of non-Hodgkin lymphoma.
Patients with chronic lymphocytic leukemia (CLL) often can live for years symptom-free. When symptoms, which can include enlarged lymph nodes and frequent infections, do appear many patients receive chemotherapy.
Researchers are testing a new targeted therapy that blocks a B-cell signaling pathway, specifically the Bruton’s tyrosine kinase (BTK), which is responsible for normal B-cell development. When that signaling goes awry, such as BTK getting stuck in the “on” position, non-Hodgkin lymphoma cells can develop and multiply.
In an early-phase study, PCI-32765, a BTK inhibitor, was shown to work against CLL, a type of non-Hodgkin lymphoma. A small group of patients who had relapsed CLL and no longer responded to standard therapy were given PCI-32765 at varying doses.
At 10 months, 70 percent of patients at the lower dose had a response to therapy, including some patients who had a reduction in lymph node size. To date, only 8 percent of patients on PCI-32765 have reported disease progression. Taking into account that nearly three-quarters of patients in the trial had at least one high-risk factor for treatment-resistant CLL, researchers are optimistic. In addition, these numbers are an improvement over the preliminary results announced last year.
Side effects of PCI-32765 included diarrhea, fatigue and nausea, but Susan O’Brien, MD, of M.D. Anderson Cancer Center in Houston, noted that myelosuppression (impaired bone marrow function), a common treatment side effect in CLL that can increase the risk of infection, was not seen with the drug.
“The efficacy is increasing over time; there is a relative lack of toxicity and lack of myelosuppression,” she said during a press briefing of the study results. “These agents will really change the paradigm for treatment of CLL.”
The drug is also showing activity against mantle cell lymphoma (MCL), a less common type of non-Hodgkin lymphoma that is particularly hard to treat. A phase 2 study found that after about four months more than two-thirds of patients with MCL responded to the drug, regardless if they had been treated with Velcade (bortezomib), a targeted therapy commonly used for the disease. Researchers are hopeful the drug will continue to be studied in a phase 3 trial for patients with MCL.
Patrick Swayze’s Widow Reflects His Cancer, Demi Moore Speaks About Breast Cancer and More
April 12th 2024From Patrick Swayze’s widow recalling his pancreatic cancer diagnosis to Demi Moore speaking about her aunt’s courage during cancer, here’s what’s going on in the oncology space this week.
Read More